Publications
POSTER PRESENTATION Thursday, February 23, 2023 – Saturday, February 25, 2023
PRESENTATION Thursday, February 09, 2023
PRESENTATION Wednesday, November 30, 2022 – Thursday, December 1, 2022
POSTER PRESENTATION Tuesday, November 29, 2022 – Friday, December 2, 2022
PRESENTATION Thursday, November 17, 2022
ARTICLE Jan Heering, Nathalie Jores, Whitney Kilu, Espen Schallmayer, Evelyn Peelen, Andreas Muehler, Hella Kohlhof, Daniel Vitt, Verena Linhard, Santosh L. Gande, Apirat Chaikuad, Sridhar Sreeramulu, Harald Schwalbe, Daniel Merk
PRESENTATION Wednesday, October 26, 2022 – Friday, October 28, 2022
POSTER PRESENTATION Wednesday, October 19, 2022 – Saturday, October 22, 2022
ARTICLE Maria J. G. T. Vehreschild, Petar Atanasov, Kateryna Yurko, Cristian Oancea, Georgi Popov, Valentina Smesnoi, Gheorghe Placinta, Hella Kohlhof, Daniel Vitt, Evelyn Peelen, Jelena Mihajlović, Andreas R. Muehler
PRESENTATION Tuesday, September 20, 2022
PRESENTATION Tuesday, July 26, 2022 – Thursday, July 28, 2022
POSTER PRESENTATION / PRESENTATION Wednesday, July 6, 2022 – Saturday, July 9, 2022
ARTICLE Robert J. Fox, Heinz Wiendl, Christian Wolf, Nicola De Stefano, Johann Sellner, Viktoriia Gryb, Konrad Rejdak, Plamen Stoyanov Bozhinov, Nataliya Tomakh, Iryna Skrypchenko, Andreas R. Muehler
POSTER PRESENTATION Friday, June 10, 2022 – Monday, June 13, 2022
ARTICLE Kim M. Stegmann et al.
ARTICLE Elizabeth J. Carey, John Eaton, Mitchell Clayton, Andrea Gossard, Sara Iqbal, Hamid Ullah, Nan Zhang, Richard Butterfield, Keith D. Lindor
POSTER PRESENTATION Wednesday, February 16, 2022 – Saturday, February 19, 2022
PRESENTATION Tuesday, December 14, 2021
POSTER PRESENTATION Wednesday, October 13, 2021 – Friday, October 15, 2021
PRESENTATION Wednesday, October 6, 2021
POSTER PRESENTATION Wednesday, September 22, 2021 – Saturday, September 25, 2021
PRESENTATION Monday, July 12, 2021
POSTER PRESENTATION Wednesday, June 30, 2021 – Saturday, July 3, 2021
PRESENTATION Thursday, July 1, 2021
POSTER PRESENTATION Saturday, April 17, 2021 – Thursday, April 22, 2021
POSTER PRESENTATION Wednesday, March 24, 2021 – Friday, March 26, 2021
PRESENTATION February 18, 2021
ARTICLE Andreas Muehler, Jason R. Slizgi, Hella Kohlhof, Manfred Groeppel, Evelyn Peelen, Daniel Vitt
ARTICLE Friedrich Hahn, Christina Wangen, Sigrun Häge, Antonia Sophia Peter, Gerhard Dobler, Brett Hurst, Justin Julander, Jonas Fuchs, Zsolt Ruzsics, Klaus Überla, Hans-Martin Jäck, Roger Ptak, Andreas Muehler, Manfred Gröppel, Daniel Vitt, Evelyn Peelen, Hella Kohlhof, Manfred Marschall
POSTER PRESENTATION Friday, September 11, 2020 – Sunday, September 13, 2020
PRESENTATION Friday, September 11, 2020
PRESENTATION Monday, August 3, 2020
ARTICLE Yu-Jin Kim, Beatrice Cubitt, Yingyun Cai, Jens H. Kuhn, Daniel Vitt, Hella Kohlhof, Juan C. de la Torre
PRESENTATION Tuesday, May 19, 2020
ARTICLE Andreas Muehler, Evelyn Peelen, Hella Kohlhof, Manfred Gröppel, Daniel Vitt
ARTICLE Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt
ABSTRACT Robert Fox, Heinz Wiendl, Nicola De Stefano, Johann Sellner, Andreas Mühler
PRESENTATION Wednesday, December 4, 2019
POSTER PRESENTATION Tuesday, October 22, 2019
ARTICLE Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt
POSTER PRESENTATION Wednesday, September 11, 2019
PRESENTATION Monday, June 24, 2019
ACTRIMS Forum 2023
Immunic’s Celiac Disease R&D Webcast
Outsourcing in Clinical Trials DACH 2022
Australasian Pharmaceutical Science Association (APSA) and Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) 2022 Joint Conference
Immunic’s Multiple Sclerosis R&D Webcast
Mechanistic Impact of Different Ligand Scaffolds on FXR Modulation Suggests Avenues to Selective Modulators
ACS Chemical Biology
Published: November 1, 2022
https://doi.org/10.1021/acschembio.2c00599
38th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
19th International Celiac Disease Symposium (ICDS)
Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
Infectious Diseases and Therapy
Published: October 15, 2022
https://doi.org/10.1007/s40121-022-00690-0
IMU-856: Phase 1 SAD/MAD Data in Healthy Human Subjects
B & T Cell-Mediated Autoimmune Disease Drug Development Summit
16th World Immune Regulation Meeting
A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis
Annals of Clinical and Translational Neurology
Published: June 14, 2022
https://doi.org/10.1002/acn3.51574
13th International Congress on Autoimmunity
Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication
iScience
Published: May 20, 2022
https://doi.org/10.1016/j.isci.2022.104293
A Pilot Study of Vidofludimus Calcium for Treatment of Primary Sclerosing Cholangitis
Hepatology Communications
Published: March 3, 2022
https://doi.org/10.1002/hep4.1926
17th Congress of ECCO (European Crohn’s and Colitis Organization)
IMU-935: Phase 1 SAD/MAD Data in Healthy Human Subjects and Preclinical Update
37th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
B&T Cell-Mediated Autoimmune Disease Drug Development Summit
50th Annual European Society for Dermatological Research (ESDR) Meeting
Virtual R&D Day: Update on the Preclinical and Clinical Development of IMU-935
The International Federation of Psoriasis Association’s 6th World Psoriasis & Psoriatic Arthritis Conference 2021
IMU-838 in Multiple Sclerosis: Phase 3 Program in RRMS & Phase 2 Trial in PMS
2021 Virtual AAN Annual Meeting
30th Annual Meeting of the Society for Virology
Main Phase 2 Analysis IMU-838 in Moderate COVID-19 & Phase 2 Proof-of-Concept Study IMU-838 in PSC
Clinical Relevance of Intestinal Barrier Dysfunction in Common Gastrointestinal Diseases
World Journal of Gastrointestinal Pathophysiology
Published: December 12, 2020
https://doi.org/10.4291/wjgp.v11.i6.114
IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro
Viruses
Published: December 5, 2020
https://doi.org/10.3390/v12121394
MSVirtual2020 / 8th Joint ACTRIMS-ECTRIMS Meeting
IMU-838 Phase 2 Data EMPhASIS Trial in RRMS
IMU-838 Phase 2 Top-Line Data EMPhASIS Trial in RRMS
Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity Against Mammarenaviruses In Vitro
Viruses
Published: July 29, 2020
https://doi.org/10.3390/v12080821
Immunic’s Inaugural Virtual R&D Day
Vidofludimus Calcium, a Next Generation DHODH Inhibitor for the Treatment of Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis and Related Disorders
Published: May 6, 2020
https://doi.org/10.1016/j.msard.2020.102129
Safety, Tolerability and Pharmacokinetics of Vidofludimus Calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects
European Journal of Drug Metabolism and Pharmacokinetics
Published: May 2, 2020
https://doi.org/10.1007/s13318-020-00623-7
Design, Rationale and Baseline Characteristics of the Randomized Double-blind Phase II Clinical Trial of Vidofludimus calcium (IMU-838) in Relapsing-Remitting Multiple Sclerosis (4558)
Neurology
Published: April 14, 2020
IBD Innovate Conference: Product Development for Crohn’s and Colitis
New York
United European Gastroenterology Week (UEGW)
Barcelona, Spain
The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study
Drugs in R&D
Published: October 16, 2019
https://doi.org/10.1007/s40268-019-00286-z
Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019
Stockholm, Sweden
GI Inflammatory Diseases Summit (GIIDS)
Boston
.